EP2068861A4 - Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication - Google Patents

Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication

Info

Publication number
EP2068861A4
EP2068861A4 EP07810680A EP07810680A EP2068861A4 EP 2068861 A4 EP2068861 A4 EP 2068861A4 EP 07810680 A EP07810680 A EP 07810680A EP 07810680 A EP07810680 A EP 07810680A EP 2068861 A4 EP2068861 A4 EP 2068861A4
Authority
EP
European Patent Office
Prior art keywords
omega
compositions
fatty acids
artery disease
peripheral artery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07810680A
Other languages
German (de)
French (fr)
Other versions
EP2068861A2 (en
Inventor
Roelof M L Rongen
Robert A Ms Shalwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliant Pharmaceuticals Inc
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of EP2068861A2 publication Critical patent/EP2068861A2/en
Publication of EP2068861A4 publication Critical patent/EP2068861A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07810680A 2006-07-21 2007-07-23 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication Withdrawn EP2068861A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83213506P 2006-07-21 2006-07-21
PCT/US2007/016526 WO2008011178A2 (en) 2006-07-21 2007-07-23 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication

Publications (2)

Publication Number Publication Date
EP2068861A2 EP2068861A2 (en) 2009-06-17
EP2068861A4 true EP2068861A4 (en) 2010-01-06

Family

ID=38957420

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07810680A Withdrawn EP2068861A4 (en) 2006-07-21 2007-07-23 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication

Country Status (3)

Country Link
EP (1) EP2068861A4 (en)
JP (1) JP2009544701A (en)
WO (1) WO2008011178A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN104146955A (en) * 2009-03-09 2014-11-19 普罗诺瓦生物医药挪威公司 Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof
WO2016152054A1 (en) * 2015-03-26 2016-09-29 備前化成株式会社 Pain prevention and alleviation effects of ω3 fatty acid glyceride
KR20210047312A (en) * 2018-08-17 2021-04-29 애머린 파마슈티칼스 아일랜드 리미티드 Methods of reducing the need for peripheral arterial revascularization in statin-treated subjects
KR20240012390A (en) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 How to Reduce Your Risk of Heart Failure

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1125914A1 (en) * 2000-02-14 2001-08-22 Nisshin Flour Milling Co., Ltd. Process for separating and purifying eicosapentaenoic acid or its ester
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO2006062932A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Treatment with omega-3 fatty acids and ppar agonist and/or antagonist and a combination product thereof
WO2006062748A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
WO2006096806A2 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
WO2007011886A2 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
EP1125914A1 (en) * 2000-02-14 2001-08-22 Nisshin Flour Milling Co., Ltd. Process for separating and purifying eicosapentaenoic acid or its ester
WO2006062932A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Treatment with omega-3 fatty acids and ppar agonist and/or antagonist and a combination product thereof
WO2006062748A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
WO2006096806A2 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
WO2007011886A2 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof

Also Published As

Publication number Publication date
WO2008011178A3 (en) 2008-06-12
JP2009544701A (en) 2009-12-17
WO2008011178A2 (en) 2008-01-24
EP2068861A2 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
EP1919468A4 (en) Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
ZA201003030B (en) Medium-chain length fatty acids and glycerides as nephroprotection agents
EP2041047A4 (en) Fatty acid blends and uses therefor
IL240454A0 (en) 3-amino-1-propanesulfonic acids and use thereof in preparation of medicaments
ZA200903860B (en) Treatment of PRDC in pigs
PL2390338T3 (en) Delta-8 desaturases and their use in making polyunsaturated fatty acids
IL195562A0 (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
EP2185202A4 (en) Use of interleukin-22 in the treatment of fatty liver disease
EP1861087A4 (en) Treatment with statin and omega-3 fatty acids and a combination product thereof
EP2136844A4 (en) Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
EP2046957A4 (en) Fatty acid desaturases and uses thereof
EP2064550A4 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
PL2214638T3 (en) Composition comprising polyunsaturated fatty acids and activated charcoal
EP2084209A4 (en) Copolymer comprising 4-hydroxybutyrate unit and lactate unit and its manufacturing method
EP2324119A4 (en) Mutant delta5 desaturases and their use in making polyunsaturated fatty acids
EP1991594A4 (en) Acrylate hybride polymer based on natural fatty acids and method for the manufacture thereof
EP2183355A4 (en) Compositions and methods for the modification of physiological responses in plants
ZA200907757B (en) Use of bipolar trans cartenoids as a pretreatment and in the treatment of peripheral vascular disease
HK1203482A1 (en) Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states pde4
EP2079526A4 (en) Compositions and uses thereof in the treatment of wounds
CL2011000290A1 (en) Method for extracting long chain polyunsaturated fatty acids; Oil composition and its use in cosmetic or therapeutic treatment.
ZA201305125B (en) Compositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyperthyroidism
EP2068861A4 (en) Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
PT2842555T (en) Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines in the treatment of diabetes
EP2099295A4 (en) Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090218

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20091204

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/06 20060101ALI20091130BHEP

Ipc: A61P 3/00 20060101ALI20091130BHEP

Ipc: A61P 43/00 20060101ALI20091130BHEP

Ipc: A61P 9/00 20060101ALI20091130BHEP

Ipc: A61K 45/06 20060101ALI20091130BHEP

Ipc: A61K 31/20 20060101AFI20090302BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100223